After disappointing Phase IIb results for avicursen last month, Percheron will adopt a three-pronged business strategy.

Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it ...

Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...

Dalton “D” Harvey has dreamed of being a firefighter his entire life. Escambia County firefighters helped make that dream ...

Delpacibart zotadirsen is under clinical development by Avidity Biosciences and currently in Phase II for Duchenne Muscular Dystrophy.

A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...

Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy.

Exciting news in the biotech industry as positive phase 2 results for sevasemten in BMD drive long-term investment potential ...

New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective ...

Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...

Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...